Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 48 articles: HTML format

Single Articles

April 2024
1. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
   Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
   Anticancer Res. 2024;44:1417-1423.
   PubMed     Abstract available
   
   
   
2. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
   Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
   Anticancer Res. 2024;44:1675-1681.
   PubMed     Abstract available
   
   
   March 2024
3. YU SH, Wang CY, Wang SS, Li JR, et al
   Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
   Anticancer Res. 2024;44:1299-1307.
   PubMed     Abstract available
   
   
   
4. SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
   Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
   Anticancer Res. 2024;44:1271-1279.
   PubMed     Abstract available
   
   
   February 2024
5. ONER M, Lin E, Chiu KY, Chen MC, et al
   p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer.
   Anticancer Res. 2024;44:543-553.
   PubMed     Abstract available
   
   
   December 2023
6. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
   Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
   Anticancer Res. 2023;43:5689-5698.
   PubMed     Abstract available
   
   
   November 2023
7. NISHIYAMA N, Kita Y, Ito K, Kato M, et al
   Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
   Anticancer Res. 2023;43:5041-5050.
   PubMed     Abstract available
   
   
   October 2023
8. SOMMER U, Grosser M, Aust D, Joehrens K, et al
   PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
   Anticancer Res. 2023;43:4365-4371.
   PubMed     Abstract available
   
   
   September 2023
9. MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
   Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
   Anticancer Res. 2023;43:4055-4060.
   PubMed     Abstract available
   
   
   
10. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    PubMed     Abstract available
    
    
    August 2023
11. TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
    Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
    Anticancer Res. 2023;43:3607-3613.
    PubMed     Abstract available
    
    
    
12. ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
    Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
    Anticancer Res. 2023;43:3615-3621.
    PubMed     Abstract available
    
    
    May 2023
13. SANO T, Aizawa R, Ito K, Nakamura K, et al
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Anticancer Res. 2023;43:2119-2126.
    PubMed     Abstract available
    
    
    April 2023
14. YAMAGUCHI N, Morizane S, Yumioka T, Shimizu R, et al
    Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:1725-1730.
    PubMed     Abstract available
    
    
    
15. LUZHA J, Nass N, Czapiewski P, Schroeder N, et al
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2023;43:1437-1448.
    PubMed     Abstract available
    
    
    
16. LEE YH, Wu RC, Mai HC, Huang WL, et al
    The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
    Anticancer Res. 2023;43:1521-1531.
    PubMed     Abstract available
    
    
    March 2023
17. CHEN SY, Chao CN, Huang HY, Zhao PW, et al
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2023;43:1175-1184.
    PubMed     Abstract available
    
    
    
18. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    PubMed     Abstract available
    
    
    January 2023
19. HASHIMOTO M, Fujita K, Tomiyama E, Fujimoto S, et al
    Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:167-174.
    PubMed     Abstract available
    
    
    
20. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
    Anticancer Res. 2023;43:269-274.
    PubMed     Abstract available
    
    
    December 2022
21. KOIZUMI M, Sato S, Yoshihara M, Nakamura Y, et al
    Chronological Change in EPHA2 Protein Expression Is Associated With Recurrence of Bladder Cancer.
    Anticancer Res. 2022;42:5783-5794.
    PubMed     Abstract available
    
    
    November 2022
22. ECKE TH, Scislowski M, Hassan N, Saura M, et al
    Luminophore Chemistry for Detection of Urinary Bladder Cancer - Comparison to Cytology and Urinary Rapid Tests (BTA stat((R)), NMP22((R)) BladderChek((R)) and UBC((R)) Rapid Test).
    Anticancer Res. 2022;42:5249-5256.
    PubMed     Abstract available
    
    
    September 2022
23. RADES D, Kopelke S, Schild SE, Kjaer TW, et al
    Evaluation of Sleep Disturbances in Patients With Bladder Cancer Scheduled for Local or Loco-regional Radiochemotherapy.
    Anticancer Res. 2022;42:4511-4515.
    PubMed     Abstract available
    
    
    August 2022
24. VASSILIOU V, Katsila T, Sodergren SC, Kardamakis D, et al
    Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications.
    Anticancer Res. 2022;42:3767-3778.
    PubMed     Abstract available
    
    
    July 2022
25. INOUE S, Sassa N, Kawanishi H, Yuguchi Y, et al
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
    Anticancer Res. 2022;42:3627-3636.
    PubMed     Abstract available
    
    
    
26. DENG F, Kong MX, Lai J
    Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
    Anticancer Res. 2022;42:3601-3605.
    PubMed     Abstract available
    
    
    
27. WALLACE B, Dekalo S, Kabha M, Mintz I, et al
    Can We Predict a Higher Risk of Urothelial Bladder Cancer With a Simple Blood Test?
    Anticancer Res. 2022;42:3569-3573.
    PubMed     Abstract available
    
    
    March 2022
28. TOMISAKI I, Harada M, Minato A, Nagata Y, et al
    Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Anticancer Res. 2022;42:1629-1634.
    PubMed     Abstract available
    
    
    
29. FURUBAYASHI N, Morokuma F, Tomoda T, Hori Y, et al
    Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
    Anticancer Res. 2022;42:1571-1577.
    PubMed     Abstract available
    
    
    
30. SALKINI MW, Yang X, Hashmi FH, Kandzari SJ, et al
    First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules - A Case Report.
    Anticancer Res. 2022;42:1339-1344.
    PubMed     Abstract available
    
    
    February 2022
31. KURASHINA R, Ando K, Inoue M, Izumi K, et al
    Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma.
    Anticancer Res. 2022;42:1131-1136.
    PubMed     Abstract available
    
    
    January 2022
32. KACZOROWSKI M, Matysiak J, Kielb P, Malkiewicz B, et al
    Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers.
    Anticancer Res. 2022;42:493-500.
    PubMed     Abstract available
    
    
    December 2021
33. WONG BS, Wu WT, Su JH, Goan YG, et al
    Flaccidoxide Induces Apoptosis Through Down-regulation of PI3K/AKT/mTOR/p70S6K Signaling in Human Bladder Cancer Cells.
    Anticancer Res. 2021;41:6123-6133.
    PubMed     Abstract available
    
    
    
34. OKUBO K, REssING N, Schulz WA, Hansen FK, et al
    The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
    Anticancer Res. 2021;41:5987-5996.
    PubMed     Abstract available
    
    
    November 2021
35. YUMIOKA T, Honda M, Shimizu R, Teraoka S, et al
    Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
    Anticancer Res. 2021;41:5767-5773.
    PubMed     Abstract available
    
    
    
36. PALACKA P, Slopovsky J, Obertova J, Chovanec M, et al
    Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Anticancer Res. 2021;41:5749-5759.
    PubMed     Abstract available
    
    
    
37. FISCHER N, Ellinger J, Koeditz B, Heidenreich A, et al
    Predictors for Outcome and Complications Related to Urinary Diversion.
    Anticancer Res. 2021;41:5585-5591.
    PubMed     Abstract available
    
    
    October 2021
38. PAN Y, Hong YC, Hsiao CH, Shih HJ, et al
    Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2021;41:4957-4968.
    PubMed     Abstract available
    
    
    August 2021
39. FOSSUM CC, Xiong Y, Magliocco A, Daneshmand S, et al
    Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2021;41:3851-3857.
    PubMed     Abstract available
    
    
    
40. MUKAE Y, Ito H, Miyata Y, Araki K, et al
    Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer.
    Anticancer Res. 2021;41:3815-3823.
    PubMed     Abstract available
    
    
    
41. MASILAMANI AP, Fischer A, Schultze-Seemann S, Kuckuck I, et al
    Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer.
    Anticancer Res. 2021;41:3741-3746.
    PubMed     Abstract available
    
    
    
42. MATSUNAGA W, Hamada K, Tagawa M, Morinaga T, et al
    Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector.
    Anticancer Res. 2021;41:3731-3740.
    PubMed     Abstract available
    
    
    June 2021
43. OKUBO K, Isono M, Asano T, REssING N, et al
    Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
    Anticancer Res. 2021;41:2901-2912.
    PubMed     Abstract available
    
    
    May 2021
44. XIAO H, Alisic H, Reiman BT, Deng Z, et al
    IL-39 Reduces Proliferation and Promotes Apoptosis of Bladder Cancer by Altering the Activity of Cyclin E and Fas.
    Anticancer Res. 2021;41:2239-2245.
    PubMed     Abstract available
    
    
    December 2020
45. ADELMANN TG, Camerota TC, Ceausu AR, Cimpean AM, et al
    Chloride Intracellular Channel Protein 1 (CLIC1) Iotas Over-expressed in Muscle Invasive Urinary Bladder Cancer.
    Anticancer Res. 2020;40:6879-6884.
    PubMed     Abstract available
    
    
    November 2020
46. PAN Y, Chiu YH, Chiu SC, Cho DY, et al
    Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Anticancer Res. 2020;40:6093-6099.
    PubMed     Abstract available
    
    
    
47. SUN YU, Nishino H, Sugisawa N, Yamamoto J, et al
    Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
    Anticancer Res. 2020;40:6083-6091.
    PubMed     Abstract available
    
    
    October 2020
48. MAJEWSKI W, Nieckula J, Dworzecki T, Miszczyk L, et al
    Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer - A Single-institution Experience.
    Anticancer Res. 2020;40:5861-5868.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.